

Madiha Derouazi, CEO, Amal Therapeutics

Madiha Derouazi has been working on vector engineering and therapeutic cancer vaccines for over 9 years. She has a strong background in applied molecular and cellular biotechnology, with research interests at the interface of fundamental and translational research, the so called bench-to-bedside. In the Laboratory of Tumor Immunology of the University of Geneva, she designed and characterised a Cell Penetrating Peptide-based multi-epitopic cancer vaccine. In 2012 she founded Amal Therapeutics to develop this vaccine platform. Madiha Derouazi holds a PhD in Biotechnology from the Ecole Polytechnique Fédérale de Lausanne (EPFL), Switzerland and a Master in Biotechnology Engineering from the University of Technology of Berlin, Germany.